The more business we did, the more we needed to know about the people we were considering working with. This was before the internet – so you couldn’t just go online and look someone up. The investigation companies only worked with big corporations and couldn’t help us. So I found the right resource and started LCF, to investigate legal, corporate and financial affairs.
RJ Valentine, Chairman The MBA GroupAlgeness by Advanced Aesthetic Technologies Inc. (AAT)
The New Benchmark for Subdermal Fillers
THE CONCEPT
Anti-wrinkle treatments have always demonstrated huge market potential, primarily among women, though men have shown increasing demand over the years. The advent of dermal fillers created a whole new sector, which was projected to reach $10 billion by 2023, primarily driven by practitioners and consumers looking for minimally invasive and non-invasive procedures. The majority of products were not only invasive, but synthetic as well, creating a window of opportunity for a filler solution that was natural, safer and simpler to use.
THE MISSION
Our team was dedicated to creating a breakthrough in fillers by offering more efficient, higher quality and safer solutions for bio-technologies in the aesthetic medical field. We strove to enable those seeking cosmetic enhancements to easily access treatment using a unique injection technique administered by physicians.
THE MBA GROUP DIFFERENCES
Research – Algeness is the culmination of 10 years of scientific and clinical research to find the most natural, biocompatible material to fill wrinkles and compensate for volume loss in facial soft tissues. We conducted studies to master the correlation between the agarose structure and the physiological response at different concentrations. The result was a 100% natural subdermal biodegradable injection that achieves immediate and lasting youthful volumizing effects without added chemicals, solvents or cross-linked agents required by Hyaluronic Acid fillers.
Marketing – As always, a premium website was the core of our marketing activities. Though our efforts were primarily focused on consumers, we created a separate campaign aimed at the medical community. Our multi-channel marketing consisted of PR, social media, videos, customer testimonials, medical expert alliances, physician training and sales materials, direct response and events.
THE RESULTS
Algeness was successfully launched in 33 countries through Europe, Asia, the Middle East and South America. After raising further equity financing and receiving FDA clearance, Algeness captured the US market and has since become the global leader in aesthetic gel implant technology.